title: Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Src is involved in multiple processes of cancer metastasis; however, its significance in HCC is not well defined. In the present study, overexpression of Src phosphorylation (Y416) was observed in the highly metastatic MHCC97H cell line; additionally, through inhibition of Src kinase activation, HCC cell proliferation, migration, invasion and colony formation were significantly reduced in vitro. Tumour growth was not affected in the orthotopic xenograft HCC model, but the metastasic potential was inhibited as revealed by reduced lung metastasic foci after administration of saracatinib. Phosphorylation level of Src pathway signalling molecules, such as Src, FAK and Stat3, were also reduced in vitro and in vivo, as a result of the anti-metastasic effects caused by saracatinib treatment. In conclusion, we demonstrated the pro-metastasic role of Src in HCC, and further experiments suggest the use of the Src inhibitor in combination with cytotoxic agents and other anticancer treatments to improve HCC prognosis.
authors.affiliation: Department of General Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, P.R. China.
authors.forename: Ju
authors.initials: J
authors.lastname: Xiong
authors.affiliation: Department of Oncology, Hainan Nonken Nada Hospital, Danzhou, Hainan 571700, P.R. China.
authors.forename: Jin-Sheng
authors.initials: JS
authors.lastname: Wu
authors.affiliation: Department of Gastroenterology, Haikou People's Hospital Affiliated to Central South University, Xiangya School of Medicine, Haikou 570028, P.R. China.
authors.forename: Shan-Shan
authors.initials: SS
authors.lastname: Mao
authors.affiliation: Department of Gastroenterology, Haikou People's Hospital Affiliated to Central South University, Xiangya School of Medicine, Haikou 570028, P.R. China.
authors.forename: Xiang-Nan
authors.initials: XN
authors.lastname: Yu
authors.affiliation: Department of Gastroenterology, Haikou People's Hospital Affiliated to Central South University, Xiangya School of Medicine, Haikou 570028, P.R. China.
authors.forename: Xiao-Xi
authors.initials: XX
authors.lastname: Huang
mesh_terms: D000818:Animals; D052117:Benzodioxoles / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009361:Neoplasm Invasiveness / Q000473:pathology; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology; D010766:Phosphorylation / Q000187:drug effects; D011799:Quinazolines / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays / Q000379:methods; D019061:src-Family Kinases / Q000378:metabolism
chemical_list: D052117:Benzodioxoles; D011799:Quinazolines; C515233:saracatinib; D019061:src-Family Kinases